Integer Holdings Co. (NYSE:ITGR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Integer Holdings Co. (NYSE:ITGR) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $120.50.

Several research analysts recently weighed in on ITGR shares. KeyCorp boosted their target price on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and boosted their target price for the company from $105.00 to $135.00 in a research note on Monday, April 15th. CL King assumed coverage on shares of Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective for the company. Finally, Benchmark upped their price objective on shares of Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, March 28th.

Institutional Trading of Integer

A number of institutional investors have recently modified their holdings of ITGR. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Integer by 497.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 536,343 shares of the medical equipment provider’s stock worth $42,065,000 after purchasing an additional 446,508 shares during the period. Norges Bank purchased a new stake in shares of Integer during the 4th quarter worth about $19,491,000. Public Employees Retirement Association of Colorado grew its holdings in shares of Integer by 3,260.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 285,439 shares of the medical equipment provider’s stock worth $28,281,000 after purchasing an additional 276,944 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Integer by 27.8% during the 4th quarter. Victory Capital Management Inc. now owns 1,154,833 shares of the medical equipment provider’s stock worth $79,060,000 after purchasing an additional 251,207 shares during the period. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of Integer by 1,226.1% during the 1st quarter. Rockefeller Capital Management L.P. now owns 223,876 shares of the medical equipment provider’s stock worth $17,350,000 after purchasing an additional 206,994 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Price Performance

Integer stock opened at $116.62 on Friday. Integer has a 52 week low of $69.40 and a 52 week high of $121.53. The company has a quick ratio of 1.71, a current ratio of 2.80 and a debt-to-equity ratio of 0.64. The firm’s 50-day simple moving average is $111.82 and its 200 day simple moving average is $98.63. The firm has a market capitalization of $3.91 billion, a PE ratio of 43.35, a P/E/G ratio of 1.63 and a beta of 1.10.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The firm had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. During the same quarter in the previous year, the company posted $1.11 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Integer will post 5.31 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.